The glucagon receptor activity of Retatrutide produces better liver fat reduction and stronger improvements in fatty liver markers both of which deteriorate with age and are core to recovery-first body composition
Zepbound and Mounjaro contain tirzepatide, which targets GIP and GLP-1 receptors
Key weight loss results at 48 weeks by group: Response rates at 48 weeks (12 mg dose): 100% achieved greater than or equal to 5% weight loss 93% achieved greater than or equal to 10% weight loss 83% achieved greater than or equal to 15% weight loss The cardiometabolic improvements were also significant, with reductions in blood pressure, triglycerides, LDL cholesterol, HbA1c, fasting glucose, and fasting insulin across all dose groups
Key findings: After 52 weeks, #tirzepatide significantly lowered concentrations of 12 out of 21 JKP proteins compared with insulin glargine
A repaglinida agente de metabolismo heptico e, portanto, pode ser usada em pacientes com insuficincia renal